ChemBriefGSK to buy cancer drug developer Nuvalent for $10.6 billion
GSK announced plans to acquire Nuvalent for $10.6 billion, aiming to expand its small-molecule kinase inhibitor portfolio for treatment-resistant cancers under new CEO Luke Miels.
cen · 2026-06-09 00:00